EUVIMEDEUVIMED entdecken
Crossref

Inhibition of human topoisomerases I and II and protein tyrosine phosphatase 1B by longchain compounds from lichens

B Waltenberger, S Hellou, O Delalande, C Rosano, S Ferron, D Iacopetta, L Pompermaier, J Ceramella, A Sauvager, J Boustie, P Uriac, V Temml und 2 weitere

Planta Medica · 01.03.2026 · 92 (03) · 213-214

DOI: 10.1055/s-0045-1814901 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Planta Medica, erschienen am 01.03.2026. Verfasst von B Waltenberger und 13 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lichens produce a diverse array of metabolites, many of which have promising bioactivities but yet remain underexplored. Among others, metabolites comprising side chains of increased length seem to be associated with noticeable bioactivities [ 1 ]. Within this study, metabolite profiling of five lichen species was conducted and seven long-chain lichen-derived metabolites – five depsides (glomellic acid, glomelliferic acid, divaricatic acid, stenosporic acid, and perlatolic acid), one depsidone (α-collatolic acid), and one diphenylether (β-collatolic acid) – were isolated using chromatographic methods. Aiming to identify new inhibitor scaffolds and to understand the impact of the length and functionalization of the side chains, they were investigated on their potential to inhibit human DNA topoisomerases I and II (hTopo I and II), therapeutic targets of anticancer agents, and protein tyrosine phosphatase 1B (PTP1B), a target whose inhibition is expected to be beneficial in the treatment of diabetes mellitus, in cell-free assays. The results demonstrated that, except for glomellic acid, all tested compounds effectively inhibited hTopo I and II. Similarly, these metabolites displayed significant inhibitory effects against PTP1B, with IC 50 values ranging from 4.01 to 19.7 μM. Molecular docking studies confirmed these results. These findings highlight the considerable potential of long-chain lichen metabolites and underline that the structural diversity of lichen compounds represents a valuable resource for developing novel bioactive molecules. Publication History Article published online: 05 March 2026 © 2026. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

Zitieren

APA

Waltenberger, B., Hellou, S., Delalande, O., Rosano, C., Ferron, S., Iacopetta, D., Pompermaier, L., Ceramella, J., Sauvager, A., Boustie, J., Uriac, P., Temml, V., Sinicropi, M. S., & Dévehat, F. L. (2026). Inhibition of human topoisomerases I and II and protein tyrosine phosphatase 1B by longchain compounds from lichens. Planta Medica, 92(03), 213-214. https://doi.org/10.1055/s-0045-1814901

Vancouver

Waltenberger B, Hellou S, Delalande O, Rosano C, Ferron S, Iacopetta D, et al. Inhibition of human topoisomerases I and II and protein tyrosine phosphatase 1B by longchain compounds from lichens. Planta Medica. 2026;92(03):213-214. doi:10.1055/s-0045-1814901

BibTeX
@article{Waltenberger2026,
  author = {Waltenberger, B and Hellou, S and Delalande, O and Rosano, C and Ferron, S and Iacopetta, D and Pompermaier, L and Ceramella, J and Sauvager, A and Boustie, J and Uriac, P and Temml, V and Sinicropi, M S and Dévehat, F Le},
  title = {Inhibition of human topoisomerases I and II and protein tyrosine phosphatase 1B by longchain compounds from lichens},
  journal = {Planta Medica},
  year = {2026},
  volume = {92},
  number = {03},
  pages = {213--214},
  doi = {10.1055/s-0045-1814901}
}
Kostenlos starten →